The ACC Scientific Session is hosted by the American College of Cardiology. The sessions provide forums for the latest practice updates and changes in care in cardiology pathways.

Videos

Dave Dixon, PharmD, discussed heart failure treatments in the pipeline and what he sees for the future of pharmacists in cardiovascular care.

Heart Failure Treatments in the Pipeline Focus on Stimulating Heart Muscle

With therapeutics developing quickly in the cardiovascular space, pharmacists are more important than ever.

Pharmacist Roles Expanding in Cardiovascular Medicine

Pharmacy Times spoke with Dave Dixon, PharmD, to learn more about his presentation titled “New Pharmacologic Therapies for Heart Failure.

Pharmacists Play Essential Roles in New Pharmacologic Therapies for Heart Failure

Articles

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Mavacamten Shows Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes for Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.

Late-Breaking Clinical Trials Show Promise in Treatments for Patients With HCM Undergoing Noncardiac Surgery

Mark Svet, MD, is the lead study author on a sub-analysis of the VOYAGER PAD study evaluating data on the use of rivaroxaban in patients with peripheral artery disease (PAD) and chronic kidney disease (CKD).

Despite Clinician Hesitancy, Data Support Use of Rivaroxaban in Patients with PAD, CKD

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Medical Therapy and Guideline Updates for Peripheral Arterial Disease 

Pharmacy Times spoke with Dipti Itchhaporia, MD, the 70th president of the American College of Cardiology (ACC).

ACC President Discusses Women in Leadership, Future of Cardiovascular Care

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.

New Pharmacologic Agents, Guidelines Can Further Progress Heart Failure Therapies

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment. 